Zacks Investment Research downgraded Nabriva Therapeutics AG – ADR (NASDAQ:NBRV) to Hold in a report released today.
- Updated: September 24, 2016
Just yesterday Nabriva Therapeutics AG – ADR (NASDAQ:NBRV) traded 1.23% higher at $7.24. Nabriva Therapeutics AG – ADR’s 50-day moving average is $7.58 and its 200-day moving average is $8.04. The last stock price is down -8.87% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 1,830 shares of NBRV traded hands, down from an average trading volume of 9,212
Zacks Investment Research has downgraded Nabriva Therapeutics AG – ADR (NASDAQ:NBRV) to Hold in a statement released on 9/23/2016.
Previously on Thursday September 08, 2016, HC Wainwright released a statement about Nabriva Therapeutics AG – ADR (NASDAQ:NBRV) increased the target price from $0.00 to $16.00. At the time, this indicated a possible upside of 1.02%.
Recent Performance Chart
Nabriva Therapeutics AG – ADR has 52 week low of $6.61 and a 52 week high of $10.69 and has a market capitalization of $0.
General Company Details For Nabriva Therapeutics AG – ADR (NASDAQ:NBRV)
Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its product pipeline includes lefamulin, a Phase Three plueromutilin antibiotic in intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), and BC-7013, a Phase One topical pleuromutilin treatment for Gram-positive infections, including uncomplicated skin and skin structure infections (uSSSSIs). In addition, the Company has completed a Phase Two clinical trial for acute bacterial skin and skin structure infections (ABSSSI) and Discovery Phase development of extended-spectrum pleuromutilins (ESPs), a pleuromutilin compound that treats Gram-negative bacteria. The Company is a spin-off of Sandoz GmbH.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.